Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Katsuhiko Nagase"'
Autor:
Hirofumi Nagai, Tsutomu Shimada, Yoshimitsu Takahashi, Mikako Nishikawa, Hiroyuki Tozuka, Yasuto Yamamoto, Osamu Niwa, Yutaka Takahara, Arimi Fujita, Katsuhiko Nagase, Kazuo Kasahara, Seiji Yano, Yoshimichi Sai
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 8, Iss 1, Pp 1-12 (2022)
Abstract Background Gefitinib and erlotinib, are epidermal growth factor receptor tyrosine kinase inhibitors, and are currently recommended for non-small cell lung cancer stage IV in the elderly and in patients with decreased performance status in th
Externí odkaz:
https://doaj.org/article/0079c9a575984d6282c483eb99d3b786
Autor:
Shoko Shimokawa, Akiko Sakata, Yukio Suga, Kazuya Isoda, Shingo Itai, Katsuhiko Nagase, Tsutomu Shimada, Yoshimichi Sai
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 5, Iss 1, Pp 1-7 (2019)
Abstract Background Ritodrine hydrochloride (RD), a β2-adrenergic agonist, is widely used as a tocolytic medication to suppress premature labor, but can cause neonatal hypoglycemia, a potentially severe side effect. We examined the incidence and ris
Externí odkaz:
https://doaj.org/article/8ff3aaf071f74f71932edd5fb3086111
Autor:
Yuki Ogawa, Katsuhiko Nagase, Arimi Ueda, Momoko Yamada, Mai Okano, Tsutomu Shimada, Yoshimichi Sai
Publikováno v:
Drug Metabolism and Pharmacokinetics. 35:534-538
Erlotinib shows pH-dependent solubility and its absorption is decreased in patients receiving gastric acid suppression therapy. Here, we examined whether administration of erlotinib in acidic solutions would improve its solubility and absorption char
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c10d9f224150c964d8cfd07d5c32d91b
https://doi.org/10.1016/j.dmpk.2020.08.003
https://doi.org/10.1016/j.dmpk.2020.08.003
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 50:81-86
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70b132c1d803a38ef377ec951cc78fcd
https://doi.org/10.3999/jscpt.50.81
https://doi.org/10.3999/jscpt.50.81
Autor:
Yuko Yokoi, Yusuke Hara, Yoshimichi Sai, Katsuhiko Nagase, Takahiro Kawakami, Akiko Kuwajima, Shingo Itai, Tsutomu Shimada, Toshinori Murayama
Publikováno v:
Proceedings for Annual Meeting of The Japanese Pharmacological Society. :PO3-12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30ae76650a20a12b0b72b85f674b3d20
https://doi.org/10.1254/jpssuppl.wcp2018.0_po3-12-11
https://doi.org/10.1254/jpssuppl.wcp2018.0_po3-12-11
Autor:
Yoshinori Hasegawa, Katsuyuki Kiura, Toshinori Murayama, Takahiro Kawakami, Shizuko Takahara, Kenichi Yoshimura, Seiji Yano, Shinji Takeuchi, Katsuhiko Nagase, Yoshikazu Kuribayashi, Koichi Goto, Yasuhito Imai, Takashi Seto, Makoto Nishio, Miyako Satouchi
Publikováno v:
The Journal of Medical Investigation. 64:317-320
Background The rearranged during transfection (RET) fusion gene was discovered as a driver oncogene in 1-2% of non-small cell lung cancers (NSCLCs). Alectinib is an approved anaplastic lymphoma kinase (ALK) inhibitor that may also be effective for RE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0802c1c4a426671d284c11455edc711
https://doi.org/10.2152/jmi.64.317
https://doi.org/10.2152/jmi.64.317
Autor:
Shinobu Shimizu, Yoshinori Hasegawa, Tadami Fujiwara, Shinji Takeuchi, Masahiko Ando, Kenichi Yoshimura, Akira Inoue, Katsuhiko Nagase, Toshiaki Takahashi, Nobuyuki Katakami, Seiji Yano
Publikováno v:
The Journal of Medical Investigation. 64:321-325
The BIM deletion polymorphism is reported to be associated with poor outcomes of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) treated with EGFR-TKIs, including gefitinib. We have shown that a histone deacetylase i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c33b74562f0d80b7439b5f626dcf59e9
https://doi.org/10.2152/jmi.64.321
https://doi.org/10.2152/jmi.64.321
Autor:
Akiko Sakata, Yoshimichi Sai, Tsutomu Shimada, Shingo Itai, Katsuhiko Nagase, Shoko Shimokawa, Kazuya Isoda, Yukio Suga
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences
Journal of Pharmaceutical Health Care and Sciences, Vol 5, Iss 1, Pp 1-7 (2019)
Journal of Pharmaceutical Health Care and Sciences, Vol 5, Iss 1, Pp 1-7 (2019)
Background Ritodrine hydrochloride (RD), a β2-adrenergic agonist, is widely used as a tocolytic medication to suppress premature labor, but can cause neonatal hypoglycemia, a potentially severe side effect. We examined the incidence and risk factors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61d4eca7c11376102b4bbcd03de91ab0
http://europepmc.org/articles/PMC6469200
http://europepmc.org/articles/PMC6469200
Autor:
Shinji, Takeuchi, Toshinori, Murayama, Kenichi, Yoshimura, Takahiro, Kawakami, Shizuko, Takahara, Yasuhito, Imai, Yoshikazu, Kuribayashi, Katsuhiko, Nagase, Koichi, Goto, Makoto, Nishio, Yoshinori, Hasegawa, Miyako, Satouchi, Katsuyuki, Kiura, Takashi, Seto, Seiji, Yano
Publikováno v:
The journal of medical investigation : JMI. 64(3.4)
The rearranged during transfection (RET) fusion gene was discovered as a driver oncogene in 1-2% of non-small cell lung cancers (NSCLCs). Alectinib is an approved anaplastic lymphoma kinase (ALK) inhibitor that may also be effective for RET fusion-po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::83f8c7d62e4d5a3196c2288ac0a0dadf
https://pubmed.ncbi.nlm.nih.gov/28955006
https://pubmed.ncbi.nlm.nih.gov/28955006
Autor:
Shinji, Takeuchi, Kenichi, Yoshimura, Tadami, Fujiwara, Masahiko, Ando, Shinobu, Shimizu, Katsuhiko, Nagase, Yoshinori, Hasegawa, Toshiaki, Takahashi, Nobuyuki, Katakami, Akira, Inoue, Seiji, Yano
Publikováno v:
The journal of medical investigation : JMI. 64(3.4)
The BIM deletion polymorphism is reported to be associated with poor outcomes of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) treated with EGFR-TKIs, including gefitinib. We have shown that a histone deacetylase i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c6ee695e5cae07b32a223607dc5e44af
https://pubmed.ncbi.nlm.nih.gov/28955007
https://pubmed.ncbi.nlm.nih.gov/28955007